Our data suggest the putative mechanism of increased atherosclerosis with FEN treatment is via the upregulation of the gene encoding type 2-neutral sphingomyelinase (nSMase 2, gene Smpd3), an alternative ceramide generation pathway (via sphingomyelin hydrolysis). This evidence concerns the gene SMPD3 and atherosclerosis.